BJU Int

1. ROKAN N, Reddy D, Dudderidge T
   Focal therapy for prostate cancer - when to refer?
   BJU Int. 2024 Mar 13. doi: 10.1111/bju.16315.
   

   >> Share

   
   
2. VAN HARTEN MJ, Roobol MJ, van Leeuwen PJ, Willemse PM, et al
   Evolution of European prostate cancer screening protocols and summary of ongoing trials.
   BJU Int. 2024 Mar 12. doi: 10.1111/bju.16311.
   

   >> Share

   
   
3. LOFFELER S, Bertilsson H, Muller C, Aas K, et al
   Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged >/=75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).
   BJU Int. 2024 Mar 12. doi: 10.1111/bju.16314.
   

   >> Share

   
   

   
   Br J Radiol

4. TAKANO S, Tomita N, Takaoka T, Niwa M, et al
   Late genitourinary toxicity in salvage radiotherapy for prostate cancer after radical prostatectomy: impact of daily fraction doses.
   Br J Radiol. 2024 Mar 11:tqae055. doi: 10.1093.
   

   >> Share

   
   

   
   Clin Cancer Res

5. ANSELMINO N, Labanca E, Shepherd PDA, Dong J, et al
   Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series.
   Clin Cancer Res. 2024 Mar 15. doi: 10.1158/1078-0432.CCR-23-2438.
   

   >> Share

   
   

   
   Eur Urol

6. ROY S, Saad F, Malone S, Agarwal N, et al
   Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study.
   Eur Urol. 2024;85:398-400.
   

   >> Share

   
   
7. FODOR A, Brombin C, Chiti A, Di Muzio N, et al
   Re: Marcin Miszczyk, Pawel Rajawa, Takafumi Yanagisawa, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. In press. https://doi.org/1
   Eur Urol. 2024 Mar 12:S0302-2838(24)02140-7. doi: 10.1016/j.eururo.2024.
   

   >> Share

   
   
8. SARTOR O
   Prostate-specific Membrane Antigen-targeted Isotope Therapy: Inherent Challenges Owing to Heterogeneity and Clonal Evolution.
   Eur Urol. 2024;85:205-206.
   

   >> Share

   
   
9. PILATZ A, MacLennan S, van den Bergh RCN, Veeratterapillay R, et al
   Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99-100.
   Eur Urol. 2024;85:313-314.
   

   >> Share

   
   

   
   Int J Urol

10. KOBAYASHI M, Matsuoka Y, Uehara S, Tanaka H, et al
    Utility of positive core number on MRI-ultrasound fusion targeted biopsy in combination with PI-RADS scores for predicting unexpected extracapsular extension of clinically localized prostate cancer.
    Int J Urol. 2024 Mar 12. doi: 10.1111/iju.15451.
    

    >> Share

    
    

    
    J Clin Oncol

11. KWAK L, Ravi P, Armstrong JG, Beckendorf V, et al
    Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.
    J Clin Oncol. 2024 Mar 12:JCO2300762. doi: 10.1200/JCO.23.00762.
    

    >> Share

    
    
12. FALLAH J, Xu J, Weinstock C, Gao X, et al
    Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    J Clin Oncol. 2024 Mar 14:JCO2302105. doi: 10.1200/JCO.23.02105.
    

    >> Share

    
    
13. MADAN RA, Yu EY, Posadas EM, Lee RJ, et al
    Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care.
    J Clin Oncol. 2024 Mar 15:JCO2302727. doi: 10.1200/JCO.23.02727.
    

    >> Share

    
    

    
    J Nucl Med

14. BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al
    Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions.
    J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075.
    

    >> Share

    
    

    
    J Urol

15. URABE F, Yoshioka T, Tashiro K, Kimura T, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:622.
    

    >> Share

    
    
16. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:623-624.
    

    >> Share

    
    
17. CAKICI MC, Ozgur Kazan H, Yildirim A
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:624-625.
    

    >> Share

    
    

    
    Oncogene

18. GUO S, Miao M, Wu Y, Pan D, et al
    DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer.
    Oncogene. 2024 Mar 13. doi: 10.1038/s41388-024-03005.
    

    >> Share

    
    

    
    PLoS Med

19. CUI H, Zhang W, Zhang L, Qu Y, et al
    Risk factors for prostate cancer: An umbrella review of prospective observational studies and mendelian randomization analyses.
    PLoS Med. 2024;21:e1004362.
    

    >> Share

    
    

    
    Prostate

20. GU J, Chery L, Gonzalez GMN, Huff C, et al
    A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening.
    Prostate. 2024 Mar 13. doi: 10.1002/pros.24686.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

21. LIN YM
    Impact of PI-RADS Upgrading Rules on Prostate Cancer Detection and Biopsy Decision-Making.
    Radiol Imaging Cancer. 2024;6:e249006.
    

    >> Share

    
    

    
    Urol Int

22. SIMSEK A, Celen S, Duran MB, Kucuker K, et al
    THE DIAGNOSTIC ACCURACY OF A COMBINATION OF PREOPERATIVE 68-Ga PSMA PET/CT AND MULTIPARAMETRIC MRI IN LOCALIZED PROSTATE CANCER.
    Urol Int. 2024 Mar 13. doi: 10.1159/000538061.
    

    >> Share

    
    

    
    Urology

23. MILLOT J, Arenas-Gallo C, Silver E, Goldman M, et al
    Major Complications and Adverse Events Related to Use of SpaceOAR Hydrogel for Prostate Cancer Radiotherapy.
    Urology. 2024 Mar 6:S0090-4295(24)00142-0. doi: 10.1016/j.urology.2023.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share